{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:53:58Z","timestamp":1792101238953,"version":"4.4.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-022-00339-4","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:11:58Z","timestamp":1647537118000},"page":"355-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer"],"prefix":"10.1038","volume":"3","author":[{"given":"Iv\u00e1n","family":"P\u00e9rez-N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Rozal\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Palomeque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sangrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Comerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hern\u00e1ndez-Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-5973","authenticated-orcid":false,"given":"Daniel Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-7572","authenticated-orcid":false,"given":"Irene Rius","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Monta\u00f1\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mar","family":"Alb\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ponomarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6473-2858","authenticated-orcid":false,"given":"Roger R.","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego M.","family":"Marzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9851-4066","authenticated-orcid":false,"given":"Lluis","family":"Morey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Voorwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-0664","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-9815","authenticated-orcid":false,"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":false,"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-6730","authenticated-orcid":false,"given":"Yibin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-4580","authenticated-orcid":false,"given":"Joan","family":"Albanell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-8744","authenticated-orcid":false,"given":"Toni","family":"Celi\u00e0-Terrassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"339_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"339_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"339_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"339_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836\u2013848 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"339_CR5","doi-asserted-by":"crossref","unstructured":"von Locquenghien, M., Rozal\u00e9n, C. & Celi\u00e0-Terrassa, T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J. Clin. Invest. 131, e143296 (2021).","DOI":"10.1172\/JCI143296"},{"key":"339_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFNgamma and lympohcytes prevent primary tomour development and shape tomour immunogenicity. Nature 410, 1107\u20131111 (2001).","journal-title":"Nature"},{"key":"339_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes, J., Jongsma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823\u2013836 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"339_CR8","doi-asserted-by":"crossref","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","DOI":"10.1038\/s41467-017-01062-w"},{"key":"339_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"New Engl. J. Med."},{"key":"339_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537\u2013542 (2017).","journal-title":"Nature"},{"key":"339_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385\u2013401 (2019).","journal-title":"Cancer Cell"},{"key":"339_CR12","doi-asserted-by":"publisher","first-page":"eabb0152","DOI":"10.1126\/scitranslmed.abb0152","volume":"12","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. et al. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci. Transl. Med. 12, eabb0152 (2020).","journal-title":"Sci. Transl. Med."},{"key":"339_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.immuni.2018.02.001","volume":"48","author":"J Agudo","year":"2018","unstructured":"Agudo, J. et al. Quiescent tissue stem cells evade immune surveillance. Immunity 48, 271\u2013285 (2018).","journal-title":"Immunity"},{"key":"339_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tibtech.2004.01.003","volume":"22","author":"M Drukker","year":"2004","unstructured":"Drukker, M. & Benvenisty, N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol. 22, 136\u2013141 (2004).","journal-title":"Trends Biotechnol."},{"key":"339_CR15","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124\u20131134 (2017).","journal-title":"Nat. Med."},{"key":"339_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ncb3533","volume":"19","author":"T Celi\u00e0-Terrassa","year":"2017","unstructured":"Celi\u00e0-Terrassa, T. et al. Normal and cancerous mammary stem cells evade interferon-induced constraint through the MIR\u2212199a-LCOR axis. Nat. Cell Biol. 19, 711\u2013723 (2017).","journal-title":"Nat. Cell Biol."},{"key":"339_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41556-018-0173-5","volume":"20","author":"Z Casta\u00f1o","year":"2018","unstructured":"Casta\u00f1o, Z. et al. IL-1\u03b2 inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat. Cell Biol. 20, 1084\u20131097 (2018).","journal-title":"Nat. Cell Biol."},{"key":"339_CR18","doi-asserted-by":"publisher","first-page":"13792","DOI":"10.1073\/pnas.1713728114","volume":"114","author":"MR Doherty","year":"2017","unstructured":"Doherty, M. R. et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc. Natl. Acad. Sci. USA 114, 13792\u201313797 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"339_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/1078-0432.CCR-09-2730","volume":"16","author":"T Di Tomaso","year":"2010","unstructured":"Di Tomaso, T. et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16, 800\u2013813 (2010).","journal-title":"Clin. Cancer Res."},{"key":"339_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/stem.2780","volume":"36","author":"M Sultan","year":"2018","unstructured":"Sultan, M. et al. Epigenetic silencing of TAP1 in aldefluor + breast cancer stem cells contributes to their enhanced immune evasion. Stem Cells 36, 641\u2013654 (2018).","journal-title":"Stem Cells"},{"key":"339_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"J-M Hsu","year":"2018","unstructured":"Hsu, J.-M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).","journal-title":"Nat. Commun."},{"key":"339_CR22","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982\u20133989 (2017).","journal-title":"Cancer Res."},{"key":"339_CR23","doi-asserted-by":"crossref","unstructured":"Dongre, A. et al. Direct and indirect regulators of epithelial-mesenchymal transition (EMT)-mediated immunosuppression in breast carcinomas. Cancer Discov. 11, 1286\u20131305 (2021).","DOI":"10.1158\/2159-8290.CD-20-0603"},{"key":"339_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","volume":"36","author":"W Su","year":"2019","unstructured":"Su, W. et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell 36, 139\u2013155 (2019).","journal-title":"Cancer Cell"},{"key":"339_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cell.2019.03.025","volume":"177","author":"Y Miao","year":"2019","unstructured":"Miao, Y. et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell 177, 1172\u20131186 (2019).","journal-title":"Cell"},{"key":"339_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.stem.2020.06.022","volume":"27","author":"L Jia","year":"2020","unstructured":"Jia, L., Zhang, W. & Wang, C.-Y. BMI1 inhibition eliminates residual cancer stem cells after PD1 blockade and activates antitumor immunity to prevent metastasis and relapse. Cell Stem Cell 27, 238\u2013253.e6 (2020).","journal-title":"Cell Stem Cell"},{"key":"339_CR27","doi-asserted-by":"crossref","unstructured":"Celi\u00e0-Terrassa, T. Mammary stem cells and breast cancer stem cells: molecular connections and clinical implications. Biomedicines 6, 50 (2018).","DOI":"10.3390\/biomedicines6020050"},{"key":"339_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/ncb1530","volume":"9","author":"M-L Asselin-Labat","year":"2007","unstructured":"Asselin-Labat, M.-L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 9, 201\u2013209 (2007).","journal-title":"Nat. Cell Biol."},{"key":"339_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","volume":"40","author":"I Ben-Porath","year":"2008","unstructured":"Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499\u2013507 (2008).","journal-title":"Nat. Genet."},{"key":"339_CR30","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/s41388-018-0656-7","volume":"38","author":"G Domenici","year":"2019","unstructured":"Domenici, G. et al. A Sox2\u2013Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene 38, 3151\u20133169 (2019).","journal-title":"Oncogene"},{"key":"339_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.stemcr.2014.11.002","volume":"4","author":"B Tang","year":"2015","unstructured":"Tang, B. et al. A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Rep. 4, 155\u2013169 (2015).","journal-title":"Stem Cell Rep."},{"key":"339_CR32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"339_CR33","doi-asserted-by":"crossref","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl. J. Med. 379, 2108\u20132121 (2018).","DOI":"10.1056\/NEJMoa1809615"},{"key":"339_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","volume":"2","author":"S Liu","year":"2014","unstructured":"Liu, S. et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2, 78\u201391 (2014).","journal-title":"Stem Cell Rep."},{"key":"339_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature04372","volume":"439","author":"M Shackleton","year":"2006","unstructured":"Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84\u201388 (2006).","journal-title":"Nature"},{"key":"339_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cell.2012.06.035","volume":"150","author":"H Gao","year":"2012","unstructured":"Gao, H. et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764\u2013779 (2012).","journal-title":"Cell"},{"key":"339_CR37","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"339_CR38","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00262-012-1200-1","volume":"61","author":"M Li","year":"2012","unstructured":"Li, M., Knight, D. A., Smyth, M. J. & Stewart, T. J. Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways. Cancer Immunol. Immunother. 61, 1255\u20131268 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"339_CR39","doi-asserted-by":"publisher","first-page":"E2337","DOI":"10.1073\/pnas.1618298114","volume":"114","author":"B Bierie","year":"2017","unstructured":"Bierie, B. et al. Integrin-\u03b24 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc. Natl Acad. Sci. USA 114, E2337\u2013E2346 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"339_CR40","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"339_CR41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820\u2013832 (2021).","journal-title":"Nat. Med."},{"key":"339_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2018.08.001","volume":"34","author":"C Dravis","year":"2018","unstructured":"Dravis, C. et al. Epigenetic and transcriptomic profiling of mammary gland development and tumor models disclose regulators of cell state plasticity. Cancer Cell 34, 466\u2013482 (2018).","journal-title":"Cancer Cell"},{"key":"339_CR43","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704\u2013715 (2008).","journal-title":"Cell"},{"key":"339_CR44","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.4049\/jimmunol.179.5.2851","volume":"179","author":"TJ Stewart","year":"2007","unstructured":"Stewart, T. J. & Abrams, S. I. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J. Immunol. 179, 2851\u20132859 (2007).","journal-title":"J. Immunol."},{"key":"339_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1440-1711.2000.00889.x","volume":"78","author":"SRMK Clarke","year":"2000","unstructured":"Clarke, S. R. M. K. et al. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol. Cell Biol. 78, 110\u2013117 (2000).","journal-title":"Immunol. Cell Biol."},{"key":"339_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jnci\/djn509","volume":"101","author":"E Vlashi","year":"2009","unstructured":"Vlashi, E. et al. In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl Cancer Inst. 101, 350\u2013359 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"339_CR47","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrg1489","volume":"5","author":"R Horton","year":"2004","unstructured":"Horton, R. et al. Gene map of the extended human MHC. Nat. Rev. Genet. 5, 889\u2013899 (2004).","journal-title":"Nat. Rev. Genet."},{"key":"339_CR48","doi-asserted-by":"crossref","unstructured":"Fernandes, I. et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Brain Behav. Immunol. 11, 139\u2013150 (2003).","DOI":"10.1016\/S1097-2765(03)00014-5"},{"key":"339_CR49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3389\/fimmu.2018.01135","volume":"9","author":"A Michalska","year":"2018","unstructured":"Michalska, A., Blaszczyk, K., Wesoly, J. & Bluyssen, H. A. R. A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type I and type II IFN responses. Front. Immunol. 9, 1135 (2018).","journal-title":"Front. Immunol."},{"key":"339_CR50","doi-asserted-by":"crossref","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","DOI":"10.1186\/s13059-017-1349-1"},{"key":"339_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"339_CR52","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai, L. et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell 39, 989\u2013998 (2021).","journal-title":"Cancer Cell"},{"key":"339_CR53","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997 (2018).","journal-title":"Cell"},{"key":"339_CR54","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/2326-6066.CIR-17-0150","volume":"5","author":"NK Brockwell","year":"2017","unstructured":"Brockwell, N. K. et al. Neoadjuvant interferons: critical for effective PD-1\u2013based immunotherapy in TNBC. Cancer Immunol. Res. 5, 871\u2013884 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"339_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"339_CR56","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","volume":"10","author":"J Skog","year":"2008","unstructured":"Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470\u20131476 (2008).","journal-title":"Nat. Cell Biol."},{"key":"339_CR57","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/ijms18020246","volume":"18","author":"S Takayanagi-Kiya","year":"2017","unstructured":"Takayanagi-Kiya, S., Kiya, T., Kunieda, T. & Kubo, T. Mblk-1 transcription factor family: its roles in various animals and regulation by NOL4 splice variants in mammals. Int. J. Mol. Sci. 18, 246 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"339_CR58","doi-asserted-by":"publisher","first-page":"37108","DOI":"10.1074\/jbc.M111.292771","volume":"286","author":"M Asim","year":"2011","unstructured":"Asim, M. et al. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. J. Biol. Chem. 286, 37108\u201337117 (2011).","journal-title":"J. Biol. Chem."},{"key":"339_CR59","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/onc.2017.97","volume":"36","author":"S Jalaguier","year":"2017","unstructured":"Jalaguier, S. et al. Complex regulation of LCoR signaling in breast cancer cells. Oncogene 36, 4790\u20134801 (2017).","journal-title":"Oncogene"},{"key":"339_CR60","doi-asserted-by":"publisher","first-page":"30275","DOI":"10.1074\/jbc.M109.051201","volume":"284","author":"A Palijan","year":"2009","unstructured":"Palijan, A. et al. Ligand-dependent corepressor LCoR is an attenuator of progesterone-regulated gene expression. J. Biol. Chem. 284, 30275\u201330287 (2009).","journal-title":"J. Biol. Chem."},{"key":"339_CR61","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","volume":"8","author":"A Mehta","year":"2018","unstructured":"Mehta, A. et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 8, 935\u2013943 (2018).","journal-title":"Cancer Discov."},{"key":"339_CR62","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.2021.39.15_suppl.1006","volume":"39","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. J. Clin. Oncol. 39, 1006 (2021).","journal-title":"J. Clin. Oncol."},{"key":"339_CR63","doi-asserted-by":"publisher","first-page":"eaat1445","DOI":"10.1126\/scitranslmed.aat1445","volume":"10","author":"IR Ruiz","year":"2018","unstructured":"Ruiz, I. R. et al. P95HER2\u2013T cell bispecific antibody for breast cancer treatment. Sci. Transl. Med. 10, eaat1445 (2018).","journal-title":"Sci. Transl. Med."},{"key":"339_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386 (2018).","journal-title":"Cell"},{"key":"339_CR65","doi-asserted-by":"publisher","first-page":"101960","DOI":"10.1016\/j.isci.2020.101960","volume":"24","author":"K Magiera-Mularz","year":"2021","unstructured":"Magiera-Mularz, K. et al. Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience 24, 101960 (2021).","journal-title":"iScience"},{"key":"339_CR66","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"339_CR67","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1093\/nar\/gkf436","volume":"30","author":"K Katoh","year":"2002","unstructured":"Katoh, K., Misawa, K., Kuma, K. I. & Miyata, T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30, 3059\u20133066 (2002).","journal-title":"Nucleic Acids Res."},{"key":"339_CR68","doi-asserted-by":"publisher","first-page":"D427","DOI":"10.1093\/nar\/gky995","volume":"47","author":"S El-Gebali","year":"2019","unstructured":"El-Gebali, S. et al. The Pfam protein families database in 2019. Nucleic Acids Res. 47, D427\u2013D432 (2019).","journal-title":"Nucleic Acids Res."},{"key":"339_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"339_CR70","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1093\/bioinformatics\/bts503","volume":"28","author":"F Garc\u00eda-Alcalde","year":"2012","unstructured":"Garc\u00eda-Alcalde, F. et al. Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics 28, 2678\u20132679 (2012).","journal-title":"Bioinformatics"},{"key":"339_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"339_CR72","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"339_CR73","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.stem.2013.10.016","volume":"13","author":"Y Wu","year":"2013","unstructured":"Wu, Y. et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13, 659\u2013662 (2013).","journal-title":"Cell Stem Cell"},{"key":"339_CR74","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/bioinformatics\/btr669","volume":"28","author":"R Schmieder","year":"2012","unstructured":"Schmieder, R., Lim, Y. W. & Edwards, R. Identification and removal of ribosomal RNA sequences from metatranscriptomes. Bioinformatics 28, 433\u2013435 (2012).","journal-title":"Bioinformatics"},{"key":"339_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"339_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s43018-019-0003-0","volume":"1","author":"G Abril-Rodriguez","year":"2020","unstructured":"Abril-Rodriguez, G. et al. PAK4 inhibition improves PD-1 blockade immunotherapy. Nat. Cancer 1, 46\u201358 (2020).","journal-title":"Nat. Cancer"},{"key":"339_CR77","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","volume":"26","author":"A Lachmann","year":"2010","unstructured":"Lachmann, A. et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438\u20132444 (2010).","journal-title":"Bioinformatics"},{"key":"339_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"339_CR79","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00339-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00339-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00339-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:23:48Z","timestamp":1733955828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00339-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1038\/s43018-022-00339-4","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IMIM has filed a patent on the findings based on this study, with T.C.-T., J. Albanell, I.P.-N. and C.R. are named as coinventors. J. Albanell has received consulting fees and honoraria from Seagen, Pfizer, AstraZeneca, Lilly, Merck, Roche, Gilead, Novartis and Daiichi-Sankyo, receives royalties from a licensed patent to Biocartis and holds stock options from Inbiomotion. J. Arribas reports grants from Roche, Synthon\/Biondys and Molecular Partners; and grants and personal fees from Menarini and Mnemo during the conduct of the study. J. Arribas has a patent for EP 0930183.5 issued, licensed and with royalties paid, a patent for P200801652 issued, licensed and with royalties paid, and a patent for EP20382457.8 pending, licensed and with royalties paid. L.C. reports being an advisory board member and receiving honoraria as speaker\u2019s bureau from Roche. L.P. has received consulting fees and honoraria from Seagen, Pfizer, Astra Zeneca, Merck, Novartis, Bristol Myers Squibb, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, Personalis, Natera and Daiichi; and institutional research funding from Seagen, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. The remaining authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}